Jang Hyun Koh
Yonsei University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jang Hyun Koh.
Diabetes Care | 2009
Jang Hyun Koh; Young Goo Shin; Soo Min Nam; Mi Young Lee; Choon Hee Chung; Jang Yel Shin
OBJECTIVE Adipocyte fatty acid-binding protein (A-FABP) is a major cytoplasmic protein in adipocytes and macrophages and is closely associated with metabolic syndrome, type 2 diabetes, and atherosclerosis. Here, we investigated whether A-FABP was associated with nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes. RESEARCH DESIGN AND METHODS We enrolled 181 type 2 diabetic patients. Clinical and biochemical metabolic parameters were measured. The severity of NAFLD was measured by ultrasound. A-FABP, adiponectin, and retinol-binding protein-4 (RBP-4) were determined by enzyme-linked immunosorbent assay. RESULTS A-FABP levels, defined as more than a moderate degree of fatty liver compared with men, those without metabolic syndrome, and those without NAFLD, were higher in women, patients with metabolic syndrome, and patients with overt NAFLD, respectively. Adiponectin was decreased according to the severity of NAFLD, but RBP-4 showed no difference. Age- and sex-adjusted A-FABP showed positive correlations with BMI, waist-to-hip ratio, waist circumference, triglycerides, gamma-glutamyltransferase, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), A1C, and C-reactive protein (CRP) but showed negative correlation with HDL cholesterol. The odds ratio (OR) for the risk of overt NAFLD with increasing levels of sex-specific A-FABP was significantly increased (OR 2.90 [95% CI 1.15-7.29] vs. 7.87 [3.20-19.38]). The OR in the highest tertile of A-FABP remained significant after adjustments for BMI, waist circumference, A1C, HDL cholesterol, triglycerides, HOMA-IR, CRP, and hepatic enzymes. CONCLUSIONS Our study demonstrates that serum A-FABP is significantly associated with NAFLD in type 2 diabetes, independent of BMI, waist circumference, HOMA-IR, A1C, triglycerides, HDL cholesterol, and CRP.
Diabetic Medicine | 2008
Mi-Young Lee; Sang Baek Koh; Jang Hyun Koh; Soo Min Nam; Jang-Yel Shin; Young Goo Shin; In Deok Kong; So Yeon Ryu; Tae Yong Lee; Jong Ku Park; Choon-Hee Chung
Aims To investigate associations between γ‐glutamyltransferase (GGT) and components of metabolic syndrome (MS), insulin resistance and inflammatory markers in the Korean population.
International Journal of Endocrinology | 2014
Jang Hyun Koh; Eun Soo Lee; Miri Hyun; Hong Min Kim; Yoon Jung Choi; Eun Young Lee; Dhananjay Yadav; Choon Hee Chung
The overexpression of vascular endothelial growth factor (VEGF) is known to be involved in the pathogenesis of diabetic nephropathy. In this study, the protective effects of taurine on diabetic nephropathy along with its underlying mechanism were investigated. Experimental animals were divided into three groups: LETO rats as normal group (n = 10), OLETF rats as diabetic control group (n = 10), and OLETF rats treated with taurine group (n = 10). We treated taurine (200 mg/kg/day) for 20 weeks and treated high glucose (HG, 30 mM) with or without taurine (30 mM) in mouse cultured podocyte. After taurine treatment, blood glucose level was decreased and insulin secretion was increased. Taurine significantly reduced albuminuria and ACR. Also it decreased glomerular volume, GBM thickness and increased open slit pore density through decreased VEGF and increased nephrin mRNA expressions in renal cortex. The antioxidant effects of taurine were confirmed by the reduction of urine MDA in taurine treated diabetic group. Also reactive oxygen species (ROS) levels were decreased in HG condition with taurine treated podocytes compared to without taurine. These results indicate that taurine lowers glucose level via increased insulin secretion and ameliorates the progression of diabetic nephropathy through antifibrotic and antioxidant effects in type 2 diabetes rat model.
Diabetes Research and Clinical Practice | 2009
Soo Min Nam; Mi Young Lee; Jang Hyun Koh; Jun Ho Park; Jang Yel Shin; Young Goo Shin; Sang Baek Koh; Eun Young Lee; Choon Hee Chung
Yonsei Medical Journal | 2007
Mi Young Lee; Eun Young Lee; Byung Jun Lee; Chan Sik Won; Jang Hyun Koh; Jang Yel Shin; Young Goo Shin; Byung Pil Cho; Choon Hee Chung
The Journal of Korean Diabetes Association | 2007
Soo Min Nam; Ho Yeol Yu; Mi Young Lee; Jang Hyun Koh; Jang Yel Shin; Young Goo Shin; Choon Hee Chung
Endocrinology and Metabolism | 2006
Soo Min Nam; Mi Yeong Lee; Jang Hyun Koh; Ki Joon Sung; Choon Hee Chung
Diabetes Research and Clinical Practice | 2008
Jang Yel Shin; Soo Min Nam; Mi Young Lee; Jang Hyun Koh; Young Goo Shin; Choon Hee Chung
Tuberculosis and Respiratory Diseases | 2007
Ki Won Jo; Jang Hyun Koh; Mi Young Lee; Feel Moon Jung; Young Goo Shin; Suk Joong Yong; Choon Hee Chung
The Korean journal of internal medicine | 2007
Jin Hon Hong; Soo Min Nam; Mi Young Lee; Jang Hyun Koh; Jang Yeol Shin; Choon Hee Chung; Mee Yon Cho